- Home
- TXMD vs NERV Comparison
TXMD vs NERV Comparison
Compare TXMD & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- NERV
- Stock Information
- Founded
- TXMD 2008
- NERV 2007
- Country
- TXMD United States
- NERV United States
- Employees
- TXMD N/A
- NERV N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- TXMD Health Care
- NERV Health Care
- Exchange
- TXMD Nasdaq
- NERV Nasdaq
- Market Cap
- TXMD 13.5M
- NERV 12.0M
- IPO Year
- TXMD N/A
- NERV 2014
- Fundamental
- Price
- TXMD $1.17
- NERV $1.68
- Analyst Decision
- TXMD
- NERV Hold
- Analyst Count
- TXMD 0
- NERV 1
- Target Price
- TXMD N/A
- NERV $5.00
- AVG Volume (30 Days)
- TXMD 35.3K
- NERV 5.8K
- Earning Date
- TXMD 08-11-2025
- NERV 08-05-2025
- Dividend Yield
- TXMD N/A
- NERV N/A
- EPS Growth
- TXMD N/A
- NERV N/A
- EPS
- TXMD N/A
- NERV 0.83
- Revenue
- TXMD $1,841,000.00
- NERV N/A
- Revenue This Year
- TXMD $427.09
- NERV N/A
- Revenue Next Year
- TXMD N/A
- NERV N/A
- P/E Ratio
- TXMD N/A
- NERV $2.05
- Revenue Growth
- TXMD 53.55
- NERV N/A
- 52 Week Low
- TXMD $0.70
- NERV $1.15
- 52 Week High
- TXMD $2.44
- NERV $3.50
- Technical
- Relative Strength Index (RSI)
- TXMD 47.76
- NERV 47.97
- Support Level
- TXMD $1.13
- NERV $1.59
- Resistance Level
- TXMD $1.24
- NERV $1.75
- Average True Range (ATR)
- TXMD 0.09
- NERV 0.09
- MACD
- TXMD 0.01
- NERV -0.02
- Stochastic Oscillator
- TXMD 73.12
- NERV 36.19
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.